- Time:
For most malignancies, early tumor detection is crucial, as it expands treatment options, reduces metastases, and ultimately improves survival rates. Despite clear clinical appeal, early detection remains a considerable diagnostic challenge since small masses of tumors often remain asymptomatic and are difficult to discern from normal tissue by imaging methods.
In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously. He’ll explain how scientists used the test to identify protein markers shared by multiple cancer types including lung, breast, colon, and ovarian tumors. Key learnings from the webinar include:
• How the innovative SomaScan® Platform was used to identify early protein biomarkers in plasma for four distinct tumor types.
• Findings that not only pinpoint biomarkers unique to each tumor type but also uncover 15 protein biomarkers shared across all cancer types, revolutionizing our understanding of cancer detection.
• The development of models to stratify tumor types and illuminate unique biological pathways of tumor cell lines.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Webinar produced with support from:
Chief Scientific Officer
SomaLogic
